Comparison of vascularity and angiogenesis in primary invasive mammary carcinomas and in their respective axillary lymph node metastases.

It is well established that the ability of a neoplasm to induce a blood supply from a pre-existing circulation (angiogenesis) is a major factor in tumour growth, invasion and metastasis. However, the angiogenic potential of metastases and their subsequent growth have not been extensively studied. The question arises: can metastatic clones induce the same level of angiogenesis as in the primary neoplasm they emanated from? In this study it is hypothesised that in the same patient the level of vascularity and angiogenesis is the same in both the primary invasive ductal carcinoma and in the axillary lymph node metastasis at the time of surgery, according to Kerbels theory of clonal-dominance. To directly address the hypothesis, morphological measures of the established blood/lymphatic circulation (vascularity) as well as estimates of angiogenesis (endothelial cell proliferation) were measured in primary tumours and directly compared to the same parameters in the corresponding lymph node metastasis in a case by case basis (n = 17). The results demonstrate varying associations between the level of vascularity and angiogenesis between matched individual tumours and their metastatic lymph nodal deposits. It is possible that either variations in the angiogenic characteristics of the metastasising clone or local or systemic promoters or inhibitors of angiogenesis influence tumour angiogenesis at the different sites.

High density of small vessels expressing the tyrosine kinase receptor KDR in primary invasive breast carcinoma correlates with axillary lymph node metastases.

Although it is generally accepted that tumour growth is angiogenesis dependent, little is known about the role of angiogenesis in the metastatic process. Recent evidence suggests that the angiogenic tyrosine kinase receptor KDR is pivotal in new vessel formation. To investigate, therefore, the association between new vessel formation in primary breast carcinoma and axillary lymph node metastasis we have used computer assisted video analysis to assess the vascular distribution as well as the level of expression of KDR in individual vessels in sections of invasive breast carcinomas, some of which had metastasized to the axillary lymph nodes and some that had not. We specifically assessed the frequency distribution, perimeter, area, and density of KDR positive vessels in the same sections of tumours. Our results show that in invasive mammary carcinoma KDR is expressed exclusively on the surface and cytoplasm of endothelial cells of approximately 71% of vessels, but the level of expression in individual vessels does not correlate with the presence of axillary lymph node metastases (P > 0.10). However, we found that small vessels express higher levels of KDR (P < 0.02) than larger vessels and that there is a significantly higher frequency of relatively small (< 90 microm in perimeter) KDR positive vessels in breast tumours that had metastasized to the axillary lymph nodes than those that had not (P < 0.001). In conclusion, increased density and frequency of KDR positive small vessels in primary invasive breast carcinoma correlates with axillary lymph node metastases.

Analysis of the TEL protein during tumour angiogenesis.

It has been proposed that breast cancer follows a programmed course of development that leads to an invasive phenotype that is associated with an increase in angiogenesis. Angiogenesis is a multistage process that requires, at its early stages, proliferation of endothelial cells, the break-down of their basement membranes, and their subsequent migration and organisation into new bud-like vascular structures. The regulation of endothelial cell proliferation and migration during angiogenesis involves the ETS family of transcription factors. The TEL gene is a member of the ETS family and may play a role in vessel formation. Vascular endothelial growth factor (VEGF) is a specific growth factor in new vessel formation and in this study its regulatory effects on TEL protein phosphorylation are detailed. The TEL protein is found to be expressed during early endothelial cell tube formation in vitro. However, smaller vessels in either tumour or ovarian angiogenesis did not express the transcription factor; only the larger mature vessels were positive. Interestingly, TEL protein expression was lost in the invasive breast carcinoma studied, whilst in normal breast tissue, hyperplasia and ductal carcinoma in-situ, TEL protein expression was seen. The loss of expression of TEL protein in invasive mammary gland carcinoma may be an important factor in the pathogenesis of breast carcinoma.

Assessment of vascularity in breast carcinoma by computer-assisted video analysis (CAVA) and its association with axillary lymph node status.

Case-control methodology was used to evaluate the significance of vascularity in small breast carcinomas with regard to the presence or absence of axillary lymph node metastases. Vascularity was assessed in 32 axillary node positive primary breast tumours (LN+ve) less than 2 cm in size and compared with 56 control axillary node negative primary tumours (LN-ve), which were matched for histological type and grade and tumour size. This study design employed computer-assisted video analysis (CAVA) to assess the total blood vessel perimeter (BVP), total blood vessel area (BVA), and total blood vessel density (BVD) throughout a tissue section that encompassed an entire cross section of the tumour and its immediate periphery. The BVA and BVD in these tumours were not significantly different between LN+ve and LN-ve groups. The LN-ve carcinomas had, on average, a significantly (P<0.05) higher total BVP (3355 microm/mm2) than LN+ve tumours (2771 microm/mm2). 'Hot spot' areas were also independently assessed by two pathologists and the same areas measured by CAVA. A strong correlation (P<0.001) between the two methods of assessment of BVD of the neovascular 'hot spots' was found; however, no association with axillary lymph node metastasis was found using either method of assessment. In conclusion, vascularity assessed by either blood vessel density or blood vessel size in primary invasive breast cancers less than 2 cm in diameter showed no association with axillary lymph node metastasis; in fact a negative association was found with total BVP of whole tumour sections and BVD in 'hot spots' using CAVA. Further, this study has established a computer-assisted method of quantifying vascularity in solid neoplasms and is a positive step towards a standardised approach to this diverse and methodologically variable area.

The ETS-related factor TEL is regulated by angiogenic growth factor VEGF in HUVE-cells.

Angiogenesis is a multistage process that requires, at its early stages, proliferation of endothelial cells, the break down of the basement membrane, and subsequent budding of new vessel-like structures. The regulation of the process of endothelial cell proliferation and migration during angiogenesis involves the ETS family of transcription factors. The TEL gene is an ETS family transcription factor that may play a role in vessel formation. VEGF is a specific growth factor in vessel formation and in this study its regulatory effects on TEL gene expression are detailed. Moreover, it was shown that the effects of VEGF are mediated through the MAP kinase pathway via ERK2. In conclusion, TEL protein is endogenously expressed by HUVE-Cells during normal growth.

Phytoestrogens reduce bone loss and bone resorption in oophorectomized rats.

To examine a potential role for phytoestrogens in postmenopausal bone loss, the oophorectomized (OOX) rat model has been used in three studies to investigate the effects of the phytoestrogens coumestrol, zearalanol and a mixture of isoflavones on estrogen-dependent bone loss. In the studies of coumestrol and zearalanol, the rats were allocated to a control group, a phytoestrogen-treated group (1.5 micromol coumestrol or 3.1 mmol zearalanol twice per week, intramuscular) or, in the coumestrol study, an estrogen-treated group (28.1 nmol, intramuscular). In the isoflavone study, the rats were allocated to a control group, an estrogen treated group or a treatment group that received 131.25 mg of phytoestrogens per week incorporated into the nonpurified rat diet. Bone mineral density was measured globally and at the spine and femur at base line and 6 wk post-oophorectomy. In the coumestrol study, blood and urine samples were collected. Compared with the control group, rats receiving coumestrol and zearalanol had significantly reduced bone loss at all sites measured. The estrogen-treated group had significantly greater bone density than the control and the coumestrol-treated groups in the spine and global measurements. Coumestrol reduced urine calcium excretion and the bone resorption markers pyridinoline and deoxypyridinoline after 1 wk of treatment. Oral isoflavone phytoestrogens had no effect on oophorectomized rats including bone loss at the dose used. Thus, for the first time, the bioactivity of coumestrol and zearalanol in preventing bone loss has been demonstrated in a well-recognized model of postmenopausal bone loss.